Trial Profile
Ofatumumab for Residual Disease and Maintenance Following Chemotherapy or Chemoimmunotherapy in Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 04 Sep 2023
Price :
$35
*
At a glance
- Drugs Ofatumumab (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Therapeutic Use
- 30 Aug 2023 Planned End Date changed from 31 Jul 2023 to 31 Jul 2024.
- 30 Aug 2023 Planned primary completion date changed from 31 Jul 2023 to 31 Jul 2024.
- 02 May 2023 Planned End Date changed from 31 Dec 2022 to 31 Jul 2023.